US2008207486A1PendingUtilityA1

Compositions and methods for the therapy and diagnosis of breast cancer

Assignee: CORIXA CORPPriority: Dec 28, 1998Filed: Oct 31, 2007Published: Aug 28, 2008
Est. expiryDec 28, 2018(expired)· nominal 20-yr term from priority
C12N 9/00C07K 2317/34A61K 2039/57A61P 37/00A61K 38/00A61P 35/00C07K 14/4748C07K 14/47C12Q 2600/156G01N 2500/00C12Q 2600/158C12Q 1/6886A61P 37/04C07K 16/3015A61K 35/12A61P 43/00C07K 2319/00G01N 33/57515A61K 40/42A61K 40/34A61K 40/24A61K 40/19A61K 40/11A61K 2239/49
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.

Claims

exact text as granted — not AI-modified
1 . An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 (a) the amino acid sequence set forth in SEQ ID NO:469;   (b) the amino acid sequence encoded by the polynucleotide of SEQ ID NO:469;   (c) amino acid sequences having at least 70% identity to the sequence set forth in SEQ ID NO:469; and   (d) amino acid sequences having at least 90% identity to the sequence set forth in SEQ ID NO:469.   
     
     
         2 . A fusion protein comprising at least one polypeptide according to  claim 1 . 
     
     
         3 . A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising a polypeptide according to  claim 1 .

Join the waitlist — get patent alerts

Track US2008207486A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.